A Novel Anti-Cancer Chemotherapeutic Agent Inhibits Glioblastoma Growth and Radiation Resistance
This potential chemotherapeutic agent to treat glioblastoma is a novel small molecule inhibitor.
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells — glioma stem cells — is responsible for glioblastoma’s tumorigenesis, treatment resistance and subsequent tumor recurrence.
A collaborative team of neuro-oncology surgeon/scientists — led by Ichiro Nakano, M.D., Ph.D., University of Alabama at Birmingham, and Maode Wang, M.D., Xi’an Jiaotong University, Xi’an, China — has discovered a unique and previously unidentified molecular mechanism that maintains glioma stem cells, and they have tested it as a potential therapeutic target in glioblastoma, using a novel small molecule inhibitor they designed and synthesized.
Click here to read more.
14th International Conference on Neurology, Neuroscience and Neuromuscular Disorders
June 17-18, 2019; Tokyo
CARS 2019 Computer Assisted Radiology and Surgery
June 18-21, 2019; Rennes, France
18th Meeting of WSSFN
June 24-27, 2019; New York
International Summer School Transnasal Endoscopic Surgery: From Sinuses to Skull Base
June 24-28, 2019; Brescia, Italy
The Society of University Neurosurgeons Annual Meeting
June 26-30, 2019; Dubrovnik, Croatia